Sivik Global Healthcare LLC Takes Position in AbbVie Inc. $ABBV

Sivik Global Healthcare LLC acquired a new position in shares of AbbVie Inc. (NYSE:ABBV) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 20,000 shares of the company’s stock, valued at approximately $4,631,000. AbbVie accounts for 1.3% of Sivik Global Healthcare LLC’s holdings, making the stock its 21st biggest holding.

Several other large investors also recently modified their holdings of the business. Brighton Jones LLC increased its stake in AbbVie by 17.4% during the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after purchasing an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC boosted its holdings in shares of AbbVie by 72.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after buying an additional 3,064 shares during the period. Dynamic Technology Lab Private Ltd bought a new stake in shares of AbbVie during the first quarter worth $383,000. Signature Estate & Investment Advisors LLC raised its holdings in shares of AbbVie by 5.1% during the first quarter. Signature Estate & Investment Advisors LLC now owns 6,530 shares of the company’s stock worth $1,368,000 after acquiring an additional 316 shares during the period. Finally, Caxton Associates LLP bought a new stake in AbbVie in the 1st quarter valued at $1,347,000. 70.23% of the stock is currently owned by institutional investors.

AbbVie Trading Up 1.7%

NYSE ABBV opened at $223.88 on Wednesday. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81. The stock has a 50 day moving average of $226.46 and a 200-day moving average of $214.67. The company has a market cap of $395.69 billion, a PE ratio of 169.61, a PEG ratio of 0.92 and a beta of 0.36.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. The business had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The firm’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same period in the previous year, the company earned $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, sell-side analysts predict that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be paid a dividend of $1.73 per share. The ex-dividend date is Friday, January 16th. This represents a $6.92 annualized dividend and a dividend yield of 3.1%. This is an increase from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio is presently 496.97%.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on ABBV shares. Hsbc Global Res upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a report on Wednesday, December 10th. Berenberg Bank upgraded AbbVie from a “hold” rating to a “buy” rating and boosted their target price for the company from $170.00 to $270.00 in a research note on Wednesday, September 17th. DZ Bank downgraded AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price target for the company. in a research report on Tuesday, November 4th. UBS Group set a $240.00 price objective on shares of AbbVie in a report on Wednesday. Finally, Bank of America increased their target price on shares of AbbVie from $220.00 to $251.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. Three analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat.com, AbbVie presently has a consensus rating of “Moderate Buy” and an average price target of $246.89.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.